VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

January, 19 2022

Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowest commercially available oral alternative Findings from Phase 1b safety portion of study support trial continuation Topline Phase 2a results expected in Q1 2022 BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment…

Read More

VYNE Therapeutics Divests Topical Minocycline Assets

January, 13 2022

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%, to Journey Medical Corporation (Nasdaq: DERM) (“Journey”). The sale, which also includes VYNE’s pipeline combination product FCD105, aligns with VYNE’s strategic plan to focus its resources on…

Read More